摘要
目的比较卡培他滨或替吉奥（S-1）联合奥沙利铂（L—OHP）治疗进展期胃癌的有效性和安全性。方法收集医院进展期胃癌术后行替吉奥或卡培他滨联合奥沙利铂化疗患者112例的病历资料，其中替吉奥＋奥沙利铂治疗组（A组）93例，卡培他滨＋奥沙利铂治疗组（B组）19例，提取病历中患者基础信息、手术、治疗剂量与疗程、完全缓解率、疾病无进展生存期及毒副反应等信息。结果112例患者均可评价疗效，A组、B组的有效率分别为60．22％和68．42％，疾病控制率为83．87％和89．50％，组间差异均无统计学意义（P〉0．05）。两组患者毒副反应主要包括血液学毒性、肝肾功能异常、恶心呕吐、腹泻、口腔溃疡等，程度以Ⅰ～Ⅱ度为主，均可耐受。结论卡培他滨或与替吉奥联合奥沙利铂治疗进展期胃癌的疗效相当，毒副反应均可耐受。
Objective To compare the efficacy and safety of capecitabine combined or S- 1 combined with oxaliplatin in treating advanced gastric cancer. Methods 112 cases of records with advanced gastric cancer were selected, including 93 cases applying S- 1 and oxaliplatin （group A）, and 19 cases applying capecitabine combined with oxaliplatin （group B）. The basic information, operation treatment, dosage and period of treatment, curative effect and adverse reaction information were retrieved from the records. Results 112 cases were all assessable The remission rate of the group A and group B were 60. 22% and 68.42%, and the disease control rate were 83.87% and 89.50% respectively, with no statistically significant difference between the two groups（ P 〉 0. 05）. The adverse reactions of the two groups included hematological toxicity, liver and kidney dysfunction, nausea and vomiting, diarrhea, oral ulcer, etc. All those were in levels 1 -2, and were well tolerated. Conclusion The effect of capecitabine or S- 1 combined with oxaliplatin in the treatment of advanced gastric cancer is similar and the adverse reactions could both be tolerable.
出处
《中国药业》
CAS
2015年第19期86-87,共2页
China Pharmaceuticals
关键词
胃癌
替吉奥
卡培他滨
奥沙利铂
化学治疗
毒副反应
gastric cancer
S - 1
capecitabine
oxaliplatin
chemotherapy, adverse reaction
